Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Investigate the efficacy, safety and tolerability of several doses of BI 1356 BS ( 0.5 mg, 2.5 mg and 5.0 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes and insufficient glycemic control. An open label treatment arm with, metformin will be used for sensitivity analysis. Population pharmacokinetics of BI 1356 BS will also be assessed.
Critère d'inclusion
- Patients with Type 2 diabetes